Turn Therapeutics Inc.

Panther Life Sciences is a privately held biotechnology company founded in 2023 and headquartered in New York, NY. The company licenses and develops new treatments utilizing dissolvable microarray patch (MAP) technology to deliver shelf-stable medicine through the skin.

Verrica Pharmaceuticals Inc.VRCA · PharmaceuticalsWest Chester, United States

63% matchPublic

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

ARS Pharmaceuticals, Inc.SPRY · PharmaceuticalsSan Diego, United States

62% matchPublic

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Headquartered in Tokyo, Japan, Seikagaku Corporation, established in 1947, specializes in the global development, manufacturing, and distribution of pharmaceuticals and medical devices, with a core focus on glycoconjugates. The company, which was formerly known as K.K. Seikagaku Kenkyusho until its name change in 1962, operates through two primary segments: Pharmaceuticals and LAL. Its product portfolio encompasses a range of therapeutic and surgical solutions. For joint health, Seikagaku provides intra-articular injections like ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX, designed to enhance joint function. The company also supplies ophthalmic surgical aids such as OPEGAN, OPEGAN Hi, and SHELLGAN, alongside MucoUp for endoscopic mucosal resection. Other notable offerings include Gel-One, a cross-linked hyaluronate hydrogel addressing knee osteoarthritis, and HERNICORE for lumbar disc herniation. Beyond finished products, Seikagaku is a supplier of bulk materials, specifically sodium hyaluronate and sodium chondroitin sulfate, which find application in various pharmaceutical and cosmetic formulations. Furthermore, the company develops and markets specialized endotoxin-detecting reagents, including Pyrochrome, ENDOSPECY, and TOXICOLOR, which are crucial for quality assurance in injectable pharmaceuticals, biological products, medical devices, manufacturing operations, and dialysate water quality. Its offerings also extend to oral care, featuring the KINUSUI Spray mouthwash. Seikagaku maintains a robust development pipeline, with promising candidates such as SI-6603 for lumbar disc herniation, SI-614 (a modified hyaluronate for dry eyes), SI-613 for osteoarthritis, SI-613-ETP targeting enthesopathy, and SI-449, a powdered adhesion barrier.

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

Bexson BiomedicalBiotechnologyUnited States

64% match

Bexson Biomedical is a US-based biopharmaceutical company situated in Santa Barbara, California, focused on the research and development of non-opioid therapeutics and drug delivery systems.